Home / Healthcare / Medical Device / Asia Pacific Insulin Pump Market

Asia Pacific Insulin Pump Market Size, Share & COVID-19 Impact Analysis, By Product Type (Pumps [Tethered Pumps, Patch Pumps, and Others] and Consumables), By Disease Indication (Type 1 Diabetes and Type 2 Diabetes), By Distribution Channel (Hospital Pharmacy and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

Report Format: PDF | Published Date: May, 2023 | Report ID: FBI107537 | Status : Published

Asia Pacific held a significant share of the global insulin pump market. The Asia Pacific insulin pump market size is projected to grow at a CAGR of 20.0% during the forecast period. The global insulin pump market is projected to grow from USD 4.60 billion in 2022 to USD 15.51 billion by 2030.


The rising need for these pumps among the underserved population in the Asia Pacific region and growing product launches by industry players are expected to boost the Asia Pacific market during the forecast period.



  • In March 2022, India Medtronic Private Limited, a wholly-owned subsidiary of Medtronic, announced the launch of MiniMed 780G system with SmartGuard technology to simplify type 1 diabetes management in India.


The Asia Pacific insulin pump market report covers the following countries/regions -  China, India, Australia, Japan, Southeast Asia, and the rest of Asia Pacific.


LATEST TRENDS


Rising Penetration of Insulin Pumps among Type 1 Diabetic Patients


The rising incidence of diabetes has significantly influenced the need for insulin and insulin delivery devices among patients suffering from type 1 diabetes. Thus, increasing product launches by key industry players and their extensive presence across the APAC region have increased awareness of insulin pumps. Moreover, rising initiatives by government agencies and healthcare providers on the advantages of these pumps over other conventional therapies will further raise the product’s awareness among patients.



  • According to a multicenter study published by the NCBI in June 2021, among 1,603 children that suffered from type 1 diabetes, 15.2% of patients reported using insulin therapy in China.


DRIVING FACTORS


Rising Government Initiatives for Diabetes Care to Offer Lucrative Opportunities for Market Growth


The demand for diabetes management is increasing owing to the rising prevalence of this disease and its risk factors, such as obesity, hypertension, and others, among the patient population. Thus, several government agencies are implementing strategic initiatives, such as diabetes care programs and insulin delivery supply schemes to boost patient awareness of these devices. Such initiatives will propel the adoption of an insulin pump, further boosting the Asia Pacific insulin pump market growth.



  • According to an article published by the Commonwealth of Australia, in November 2022, the Albanese Government subsidised access to the next generation of Omnipod insulin pumps to 130,000 Australians living with type 1 diabetes. The government is providing disposable pods through the National Diabetes Services Scheme (NDSS) at community pharmacies in Australia.


RESTRAINING FACTORS



Lack of Reimbursement Policies in Developing Countries to Limit Pump Sales


The need for insulin pumps is rising across the Asia Pacific region for blood glucose control and diabetes self-management among patients. However, the costs associated with insulin pump therapy and its consumables are high. The lack of reimbursement policies for these pumps by healthcare agencies and health insurers is limiting their adoption across developing countries. Moreover, rising diabetes treatment costs in these countries will further hamper the market growth.



  • According to an article published by the NCBI in June 2022, there is no reimbursement for these pumps and related supplies in China.


KEY INDUSTRY PLAYERS


In terms of the competitive landscape, Medtronic, Insulet Corporation, and Tandem Diabetes Care, Inc. are the major players in the Asia Pacific market with high growth rates recorded in 2022. This is owing to the extensive presence of advanced products and active involvement of companies in R&D investments to accelerate product launches during the forecast period.


Other prominent players, such as Terumo Corporation and SOOIL Developments Co., Ltd., are focusing on strengthening their product portfolios by launching technologically advanced devices and consumables across the region. This is further augmenting the Asia Pacific insulin pump market share.



  • In June 2020, SOOIL Developments Co. Ltd. announced the launch of a two-way communication insulin pump 'Dana i' for diabetic patients in South Korea. The pump enabled non-face-to-face communication and treatment delivery between doctors and patients.


LIST OF KEY COMPANIES PROFILED:



  • Medtronic (Ireland)

  • Tandem Diabetes Care, Inc. (U.S.)

  • Insulet Corporation (U.S.)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Terumo Corporation (Japan)

  • MicroTech Medical, Inc. (China)

  • EOFLOW CO., LTD. (Korea)

  • Ypsomed (Switzerland)

  • SOOIL Developments Co., Ltd (Korea)


KEY INDUSTRY DEVELOPMENTS:



  • October 2021: EOFlow Co., Ltd., a provider of wearable drug delivery solutions, announced the establishment of a joint venture company SINOFLOW Co., Ltd. in China with Changsha Sinocare Co., Ltd. to enter the ever-expanding Chinese diabetes market. The joint venture company will launch a clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China.

  • November 2020: Diabeloop, a pioneer in therapeutic AI, and Terumo Corporation signed an agreement for the joint development of an Automated Insulin Delivery (AID) solution with exclusive distribution rights in Japan. The Diabeloop-developed system integrated Terumo’s innovative insulin patch pump.


REPORT COVERAGE



The research report provides a detailed market analysis. It focuses on key aspects, such as the launch of new products, technological advancements, and the prevalence of diabetes. Besides this, the report offers valuable insights into the recent market trends and highlights key industry developments, such as mergers, partnerships, and acquisitions, along with the impact of COVID-19 on the market. In addition to the above-mentioned factors, the report encompasses several factors that have contributed to the market's growth in recent years.


Report Scope & Segmentation


























































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 20% from 2023 to 2030



Unit



Value (USD billion)



Segmentation



Type; Diabetes Type; Distribution Channel; and Country/Sub-Region



By Type




  • Pumps

    • Tethered

    • Patch

    • Others



  • Consumables



By Diabetes Type




  • Diabetes 1

  • Diabetes 2



By Distribution Channel




  • Hospital Pharmacies

  • Retail & Online Pharmacies



 


By Country/Sub-Region




  • China (By Diabetes Type)

  • India (By Diabetes Type)

  • Japan (By Diabetes Type)

  • Australia (By Diabetes Type)

  • Southeast Asia (By Diabetes Type)

  • Rest of Asia Pacific (By Diabetes Type)


Frequently Asked Questions

At what CAGR is the Asia Pacific Insulin Pump market projected to grow during the forecast period of 2023-2030?

Recording a CAGR of 20%, the market will exhibit steady growth during the forecast period of 2023-2030.

What are the key factors driving the Asia Pacific Insulin Pump market?

Rising prevalence of diabetes and increasing demand for these pumps among the regional population are some of the key factors driving the market.

Who are the major players in this market?

Medtronic, Insulet Corporation, and Tandem Diabetes Care, Inc., are the major market players in Asia Pacific.

Which country held the highest share of the market?

Japan dominated the market in 2022.

  • APAC
  • 2022
  • 2019-2021
  • 80
  • PRICE
  • $ 3850
    $ 4850
    $ 5850
    Buy Now

Healthcare Clients